STOCK TITAN

SR One funds disclose 3.31M-share Avalyn Pharma (AVLN) position after IPO

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

SR One-affiliated funds disclosed a 7.5% stake in Avalyn Pharma Inc. following the company’s IPO. SR One Fund II Aggregator and AMZL collectively hold 3,308,649 shares of Avalyn common stock, compared with 44,312,047 shares outstanding as of May 1, 2026.

The stake arose from Avalyn’s IPO of 19,166,667 shares at $18.00 per share and prior purchases of Series C-1 and Series D preferred stock that automatically converted into common stock at closing. The funds state they acquired the shares for investment purposes and may buy or sell more depending on market conditions.

The investors have registration rights under an Investors’ Rights Agreement, including demand, Form S-3 and piggyback rights once conditions are met, and are subject to a 180-day IPO lock-up restricting sales and related transactions without underwriter consent.

Positive

  • None.

Negative

  • None.
IPO size 19,166,667 shares Common stock sold in Avalyn IPO, including 2,500,000 option shares
IPO price $18.00 per share Price paid by SR One Fund II Aggregator and AMZL in the offering
SR One total stake 3,308,649 shares Fund Shares of Avalyn common stock held collectively by the Funds
Ownership percentage 7.5% Percent of Avalyn common stock beneficially owned, based on 44,312,047 shares
Shares outstanding 44,312,047 shares Avalyn common stock outstanding as of May 1, 2026
SR One Fund II Aggregator holding 2,186,562 shares Common stock held by SR One Fund II Aggregator after IPO and conversions
AMZL holding 1,122,087 shares Common stock held by AMZL after IPO and conversions
Lock-up period 180 days Duration after April 29, 2026 restricting sales and related transactions
Investors' Rights Agreement financial
"each Fund and certain other stockholders of the Issuer entered into an Amended and Restated Investors' Rights Agreement"
registrable securities financial
"The Investors' Rights Agreement grants the parties thereto, including the Funds, certain registration rights in respect of registrable securities."
piggyback registration rights financial
"the stockholders party to the Investors' Rights Agreement will be entitled to certain "piggyback" registration rights allowing them to include their registrable securities"
A contractual right that lets existing shareholders join a company’s planned public sale of stock so they can sell their own shares at the same time under the same paperwork. It matters to investors because it gives insiders and early holders an easier, often faster way to convert shares to cash, while also potentially increasing the number of shares offered and affecting the share price — like catching a scheduled bus instead of hiring a private ride to get where you need to go.
lock-up agreement financial
"each Fund entered into a lock-up agreement in connection with the IPO whereby each Fund has agreed, subject to certain exceptions"
A lock-up agreement is a contract that prevents company insiders and early investors from selling their shares for a fixed period after a stock sale, often after an initial public offering. It matters to investors because it temporarily limits the number of shares that can hit the market, which can keep the share price steadier; when the lock-up ends, a sudden increase in available shares can create extra volatility, revealing insiders’ confidence or lack thereof.
Deemed Liquidation Event financial
"These registration rights will expire on the earlier of (i) the closing of a "Deemed Liquidation Event" (as defined in the Issuer's amended and restated certificate of incorporation)"
Schedule 13D regulatory
"The percentage of outstanding shares of Common Stock which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet."
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.





05348Y105

(CUSIP Number)
Sasha Keough
c/o SR One Capital Management, LP, 929 Main Street, Suite 200
Redwood City, CA, 94063
(410) 800-7503

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
05/01/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


SR One Capital Management, LLC
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:05/08/2026
SR One Capital Fund II Aggregator, LP
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:05/08/2026
SR One Capital Partners II, LP
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:05/08/2026
AMZL, LP
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:05/08/2026
SR One Capital SMA Partners, LP
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:05/08/2026
Simeon George
Signature:/s/ Sasha Keough
Name/Title:Sasha Keough, as attorney-in-fact for Simeon George, M.D.
Date:05/08/2026
Comments accompanying signature:
This Statement was executed by Sasha Keough on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

FAQ

How much of Avalyn Pharma (AVLN) do SR One-affiliated funds own?

SR One-affiliated funds report beneficial ownership of 3,308,649 shares of Avalyn Pharma common stock, representing 7.5% of the 44,312,047 shares outstanding as of May 1, 2026, based on Avalyn’s IPO prospectus disclosure.

How did SR One’s stake in Avalyn Pharma (AVLN) arise around the IPO?

SR One’s stake came from Avalyn’s IPO and earlier preferred stock investments. The funds bought IPO shares at $18.00 and previously purchased Series C-1 and Series D preferred shares that automatically converted into common stock immediately before the IPO closing.

What specific shareholdings do SR One Fund II Aggregator and AMZL have in Avalyn Pharma (AVLN)?

SR One Fund II Aggregator holds 2,186,562 Avalyn common shares, while AMZL holds 1,122,087 shares. Together, these funds own 3,308,649 shares, which the Schedule 13D filing states equal 7.5% of Avalyn’s outstanding common stock.

What registration rights do SR One-affiliated funds have for Avalyn Pharma (AVLN) shares?

Under an Investors’ Rights Agreement, the funds have demand, Form S-3 and piggyback registration rights. They can request registrations once thresholds such as at least $5 million in aggregate offering price and minimum percentages of registrable securities outstanding are met.

Are SR One-affiliated funds currently restricted from selling Avalyn Pharma (AVLN) shares?

Each fund entered a 180-day lock-up starting April 29, 2026. During this period, they generally may not sell, pledge, or hedge Avalyn common shares, or file registration statements, without prior written consent from the IPO underwriters’ representatives.

What proportion of Avalyn Pharma (AVLN) shares outstanding underlies the Schedule 13D percentages?

The reported ownership percentages use 44,312,047 Avalyn common shares outstanding as of May 1, 2026. This figure, including underwriters’ exercised option shares, comes from Avalyn’s April 29, 2026 prospectus filed under Rule 424(b)(4).